Key Highlights

  • Galera Therapeutics (OTC: GRTX) will implement a 1-for-200 reverse stock split effective July 12, 2026.
  • Every 200 shares of common stock will convert into one share following the split.
  • Existing stock options and warrants will be modified to reflect the new share structure.
  • Fractional shares will be settled in cash based on the pre-split closing market price.

Reverse Split Approved

Galera Therapeutics Inc. Has received board approval for a 1-for-200 reverse stock split of its common stock, par value $0.001. The decision aligns with the company’s strategic objectives as it advances its clinical programs targeting radiation-induced side effects in cancer treatment.

Effective Date Set

The reverse stock split will become effective at 11:59 p.m. Eastern Time on July 12, 2026. Beginning July 13, 2026, the company’s shares will trade on a post-split basis on the OTCQB Market.

Share Conversion Mechanics

Following the split, each group of 200 shares of Galera Therapeutics’ common stock will be consolidated into a single share. Shareholders will not receive fractional shares; instead, any fractional entitlements will be converted to cash payments based on the stock’s closing price immediately before the split.

Impact on Equity Compensation

The company’s equity compensation arrangements will be updated to account for the reverse split. Existing stock options will be recalibrated, with exercise prices adjusted to maintain proportional value relative to the new share count.

Warrant Adjustments

Outstanding warrants will be modified in accordance with the reverse split. The terms of these warrants, including the number of shares they represent and their exercise prices, will be revised to reflect the consolidation of shares.

Fractional Share Payouts

Investors holding positions that result in fractional shares after the split will receive cash compensation. The payout amount will be determined using the closing market price of Galera Therapeutics’ common stock on the final trading day prior to July 12, 2026.

Compliance and Filing

Galera Therapeutics has submitted the required regulatory filings under the Securities Exchange Act of 1934. The reverse stock split does not change the par value of the common stock, which remains at $0.001 per share. The move reflects the company’s efforts to optimize its capital structure while continuing its focus on developing therapies for oncology supportive care.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.